News

Terumo Health Outcomes Announces Distribution Agreement for Caretaker Medical’s VitalStream® Non-Invasive Hemodynamic Monitoring

Terumo Health Outcomes (THO), a division of Terumo Interventional Systems (TIS), today announced a new U.S. distribution agreement with Caretaker Medical to offer Caretaker Medical’s VitalStream wearable hemodynamic monitoring platform to hospitals nationwide. This agreement is yet another step in THO’s continued effort to bring forward-looking technologies to cardiovascular care teams seeking smarter, more efficient ways to monitor patient status and act sooner in the care process.

“We’re excited to partner with Terumo Health Outcomes to deliver impactful solutions for the early identification and improved treatment of shock and heart failure,” said Jeff Pompeo, CEO, Caretaker Medical. “Our VitalStream platform’s capability to deliver real-time, beat-by-beat physiological data – including continuous blood pressure and hemodynamics through a comfortable, non-invasive wearable – is central to this.”

Together, THO and Caretaker Medical are enabling clinicians to detect changes sooner and respond with confidence by eliminating invasive lines and bulky wires, especially in high-acuity cardiovascular settings like cath labs and cardiac step-down units – where timely and accurate intervention for these conditions is critical.

“Clinicians need reliable, non-invasive options for continuous monitoring, particularly in settings where invasive lines aren’t feasible or desired,” said Ghada Farah, President of Terumo Interventional Systems, Cardiac and Vascular Company at Terumo. “Caretaker’s VitalStream technology fits our mission of delivering tools that support earlier intervention and more informed decisions, while also helping hospitals improve clinical workflows and patient safety.”

THO is a division of TIS, which offers a portfolio of high-quality interventional devices that complement the predictive insights offered by THO’s ePRISM platform. While ePRISM assists clinicians in identifying patient risk and optimizing treatment strategies, the advanced tools from TIS support procedural efficiency, contributing to improved patient outcomes. This combination assists clinicians to make more informed decisions, facilitating smoother procedures and potentially reducing hospital costs and recovery times. Learn more at www.terumohealthoutcomes.com.

 

Read more here.

Recent News

05/08/2026

RIVANNA Receives FDA 510(k) Clearance for Accuro XV Musculoskeletal Ultrasound Imaging System

RIVANNA®, developer of AI-enabled clinical decision-support solutions, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Accuro® XV Diagnostic Ultrasound System. The clearance marks a pivotal regulatory milestone for RIVANNA, authorizing commercial use of the Accuro XV for musculoskeletal imaging by qualified and trained healthcare professionals in hospital

05/06/2026

RoVa Labs Opens as Transformational Investment in Roanoke Region’s Innovation Economy

Leaders from Carilion Clinic, the City of Roanoke, Roanoke Blacksburg Innovation Alliance (RBIA), and Virginia Western Community College cut the ribbon on years of hard work with the opening of RoVa Labs, a 40,000-square-foot biotech incubator designed to accelerate commercialization, strengthen the Roanoke Innovation Corridor, and position the region as an emerging destination for life

05/04/2026

ISOThrive Reports Highly Statistically Significant Phase 2 Data for MHS-1031 in NERD PPI-Partial Responder Patients at DDW 2026

ISOThrive Inc. announced positive Phase 2 results for MHS-1031 treating NERD patients with incomplete response to proton pump inhibitors (PPIs), demonstrating statistically significant and clinically meaningful reductions in heartburn incidence, severity, and regurgitation. The company’s Chief Medical Officer is presenting these results at Digestive Disease Week (DDW) 2026 this week. NERD represents approximately 70% of